ACG: Hormone Therapy Tied to Higher Risk for New Irritable Bowel Syndrome
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 31, 2024 -- Hormone replacement therapy (HRT) is associated with an increased risk for developing irritable bowel syndrome (IBS) in postmenopausal women, according to a study presented at the annual meeting of the American College of Gastroenterology, held from Oct. 25 to 30 in Philadelphia.
Jacqueline Khalil, D.O., from Case Western Reserve University in Beachwood, Ohio, and colleagues investigated the effects of HRT on IBS and its related symptoms, medication use, and diagnostic testing in postmenopausal women. The analysis included 46,627 postmenopausal women (50 years and older) with and without a prescription for HRT (estrogen and progesterone) propensity matched (1:1) for age, race, ethnicity, ulcerative colitis, Crohn disease, and celiac disease.
The researchers found that among women prescribed HRT, 992 developed IBS at least 30 days after being prescribed HRT versus 581 not prescribed HRT (odds ratio [OR], 1.75). Over five years, these associations persisted in a sensitivity analysis (OR, 1.88). At least 30 days after being prescribed HRT, 235 postmenopausal women had a new encounter diagnosis ICD code of IBS with diarrhea (OR, 1.44), 188 with IBS with constipation (OR, 2.27), and 148 with mixed IBS (OR, 1.63) compared with those not on HRT. There were increased gastrointestinal symptoms, including abdominal distention (OR, 1.44), associated with HRT. Diagnostic procedures such as colonoscopy (OR, 2.08) and esophagogastroduodenoscopy (OR, 1.21) were more frequently performed in women taking HRT.
"These findings emphasize the importance of considering the potential consequences of HRT in postmenopausal women, particularly regarding IBS," the authors write.
One author disclosed ties to Allurion, Bristol Myers Squibb, Johnson & Johnson, and Vibrant.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-01 06:00
Read more
- Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus in Primary Biliary Cholangitis (PBC)
- Shorla Oncology Announces U.S. FDA Expanded Approval of Jylamvo (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
- Ozempic Curbs Kidney Disease in Obese People Without Diabetes
- Poll Finds Most Americans Stressed Over Election, Future of Nation
- Skin Patch Uses 'Imperceptible' Electric Zaps to Heal Wounds Without Drugs
- Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions